Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MF1 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Canbridge Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's Days Payable falls into.
Canbridge Pharmaceuticals Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Canbridge Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals (FRA:MF1) has a Days Payable of 11,895.93 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Canbridge Pharmaceuticals and its competitors. This is 535% above median its historical median of 1,872.55. Over the past decade, Canbridge Pharmaceuticals' Days Payable has ranged from 942.64 to 10,785.01. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #29 out of 702 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Canbridge Pharmaceuticals' Days Payable too high?
Canbridge Pharmaceuticals' current Days Payable of 11,895.93 is 535% above median its 10-year median of 1,872.55. Over the past 10 years, this metric has ranged from a low of 942.64 to a high of 10,785.01. The Biotechnology industry median Days Payable is 113.10. Canbridge Pharmaceuticals' value of 11,895.93 is 10418.1% above this industry median. Based on the distribution chart, Canbridge Pharmaceuticals ranks #29 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #29 out of 702 companies for Days Payable. This places Canbridge Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Canbridge Pharmaceuticals' value of 11,895.93 is 10418.1% above this benchmark. Historically, Canbridge Pharmaceuticals' own Days Payable has ranged from 942.64 to 10,785.01 over the past decade. While the company's 10-year median is 1,872.55 vs. the industry median of 113.10, Canbridge Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canbridge Pharmaceuticals's current Days Payable of 11,895.93 is 10418.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Canbridge Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canbridge Pharmaceuticals's current Days Payable is 11,895.93, which is 535% above median its own 10-year median of 1,872.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Canbridge Pharmaceuticals (FRA:MF1) has a current Days Payable of 11,895.93. The stock's GF Value™ is €0.03, compared to a current price of €0.17 — trading 473.3% above its estimated fair value. The current Days Payable is 11,895.93, which is 535% above median its 10-year median of 1,872.55 and 10418.1% above the Biotechnology industry median of 113.10. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Canbridge Pharmaceuticals (FRA:MF1), the current Days Payable is 11,895.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (FRA:MF1) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.17 is trading 473.3% above its estimated GF Value™ of €0.03.
Key valuation signals for FRA:MF1:
Days Payable: 11,895.93 (535% above median its 10-year median of 1,872.55)
GF Value™: €0.03 vs. price of €0.17 (473.3% above fair value)
Industry Position: 10418.1% above the Biotechnology median (#29 of 702)
No single metric tells the full story. See the FRA:MF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for FRA:MF1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MF1 has been successfully added to your 
